Subsequent Events - Additional Information (Detail) - Daiichi Sankyo, Inc ("Daiichi") - USD ($)	1 Months Ended
	Oct. 31, 2016	Jun. 30, 2013
Subsequent Event [Line Items]
Collaborative arrangement upfront payment to be received		$ 6,000,000
Subsequent Event
Subsequent Event [Line Items]
Collaborative arrangement upfront payment to be received	$ 15,000,000
Subsequent Event | FDA and EMA
Subsequent Event [Line Items]
Aggregate amount in substantive milestones of clinical collaboration agreement deleted related to scaled commercial materials	$ 2,500,000
Percentage of royalty obligated to pay of net global commercial sales	1.00%
Aggregate payment reached for royalty obligation	$ 8,000,000
Maximum | Subsequent Event
Subsequent Event [Line Items]
Additional potential clinical milestone payments receivable	$ 10,000,000